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Benign hereditary chorea (BHC) (MIM 118700) is an autosomal dominant movement disorder. The early onset
of symptoms (usually before the age of 5 years) and the observation that in some BHC families the symptoms
tend to decrease in adulthood suggests that the disorder results from a developmental disturbance of the
brain. In contrast to Huntington disease (MIM 143100), BHC is non-progressive and patients have normal or
slightly below normal intelligence. There is considerable inter- and intrafamilial variability, including
dysarthria, axial dystonia and gait disturbances. Previously, we identified a locus for BHC on chromosome 14
and subsequently identified additional independent families linked to the same locus. Recombination
analysis of all chromosome 14-linked families resulted initially in a reduction of the critical interval for the
BHC gene to 8.4 cM between markers D14S49 and D14S278. More detailed analysis of the critical region in a
small BHC family revealed a de novo deletion of 1.2Mb harboring the TITF-1 gene, a homeodomain-
containing transcription factor essential for the organogenesis of the lung, thyroid and the basal ganglia.
Here we report evidence that mutations in TITF-1 are associated with BHC.
INTRODUCTION
Benign hereditary chorea (BHC) (MIM 118700) is an
autosomal dominant movement disorder. The disorder man-
ifests itself before the age of 5 years, running a stationary or
only slightly progressive course (1,2). The intelligence is
normal or slightly below normal, and mental deterioration as
found in Huntington disease (HD) (3,4) is not seen. In some
families, the choreic movements tend to decrease during
adolescence or early adulthood (5). The early onset of
symptoms and the observation that symptoms tend to decrease
in adulthood suggest that the disorder results from a
developmental disturbance of the brain.
Since the first BHC report in 1966 (6), a large number of
families have been reported (7). These families show
considerable intra- and interfamilial phenotypic variation.
Some exhibit additional atypical features such as axial or
extremity dystonia, myoclonic jerks, dysarthria and gait
disturbances (8). In many families, another diagnosis — such
as HD, ataxia telangiectasia or benign essential myoclonus —
was made during follow-up (9–11), leading some authors to
doubt the existence of BHC as a separate disorder (12).
Previously, we identified a locus for BHC on chromosome 14
(13), and this finding was confirmed in an independent family
(14). Since our original report, we have identified additional
independent families linked to the same locus, as well as BHC
families that provided evidence for non-linkage to chromosome
14, demonstrating that BHC is a genetically heterogeneous
disorder (G.J. Breedveld et al., in preparation). Recombination
analysis of the chromosome 14-linked families resulted initially
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in a reduction of the critical interval for the BHC gene to 8.4 cM
between markers D14S49 and D14S278 (G.J. Breedveld et al., in
preparation). More detailed analysis of the critical region in a
small BHC family revealed a de novo deletion of 1.2 Mb. Several
genes were identified in this region, including the thyroid
transcription factor 1 gene (TITF-1), also known as NKX2.1,
T/EBP and TTF-1, of the NK2 family of homeodomain-
containing transcription factors (15–18). Although most studies
of TITF-1 have focussed on its role in thyroid and lung
development, evidence from TITF-1 knockout mice demon-
strates that the gene is essential for the differentiation of the
striatum and the developing brain (19–22). Given its function,
TITF-1 is therefore an excellent candidate gene for BHC. Here
we report evidence that mutations in TITF-1 are associated with
BHC.
RESULTS
Four independent BHC families were studied. Linkage to
chromosome 14 has been previously described for Dutch
family 1 (NL1) (13), and a large family from the USA (US1)
(23) (G.J. Breedveld et al., in preparation). In an Italian family
(IT1) (24) and a family from the UK (UK1) (5), linkage to
chromosome 14 could be neither confirmed nor excluded
because of the limited numbers of samples available for testing.
Analysis of markers from chromosome 14 in family IT1
revealed a lack of transmission of the maternal allele for the
short tandem repeat (STR) marker D14S1017 from individual
II-4 to III-1 (Fig. 1). To exclude a polymorphism within a
primer sequence, or other technical reasons for the failure of
the amplification of this allele, new primers were designed for
this marker and tested. We confirmed the lack of transmission
of the maternal allele, suggesting that a de novo deletion within
the maternal chromosome had occurred (Fig. 1). To define the
exact borders of this deletion, we developed several new
polymorphic STR markers, on the basis of known genomic
sequence, within the region and tested them on the family. The
proximal boundary of the deletion could be pinpointed between
markers CGR67 and CGR46, whereas the distal boundary was
placed between CGR58 and CGR69, a region spanning
about 1.2 Mb on the genomic level (Fig. 2). Subsequently,
the deletion was confirmed by two-color FISH hybridization
(Fig. 3) using two bacterial artificial chromosome (BAC) clones
Figure 1. Haplotype reconstruction of eight chromosome 14q13.1 STR markers in family IT1, showing that a de novo deletion within a grandmaternal allele
(individual I-2) is inherited by individuals II-4 and III-1. Black symbols represent BHC-affected individuals, open symbols represent unaffected individuals.
The hatched boxes indicate the minimum deletion region defined by hemizygosity of marker CGR46 in person II-4 and marker CGR69 in person III-1. The
maximum deletion region is defined owing to heterozygosity of marker CGR58 in person II-4 and marker CGR67 in person III-1.
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Figure 2. Genomic organization of the TITF-1 gene. (A) An 8 Mb region of chromosome 14q13.1 is shown with the deletion interval found in family IT1 and STR
markers. (B) Overlapping BAC contig; STR markers and annotated genes of the 1.2 Mb deletion interval. (C) Genomic organization of the TITF-1 gene, consisting
of three exons spanning 3.8 kb; ATGs indicate both start codons of the ORF; conserved domains are indicated by black boxes. TITF-1 mutations found in families
US1 (G713T), NL1 (C727A) and UK1 (DG908) are indicated. (D) Partial amino acid sequence surrounding identified mutations and predicted amino acid changes
(in bold) resulting from the G713T, C727A and DG908 mutations, respectively.
Figure 3. Two-color FISH analysis using chromosome 14q11 BAC 2577N12 (red signal) and chromosome 14q13.1 BAC 552K16 (green signal) on metaphase and
interphase chromosomes derived from a culture of EBV-transformed lymphocytes of BHC patient III-1 in family IT1. Both chromosome 14 homologues display a
red signal, whereas only one chromosome 14 showed a green signal indicating a genomic deletion of BAC 552K16 sequences.
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as probes. BAC clone RP11-552K16 lies within the apparent
genomic deletion, between markers CGR69 and D14S1017
(Fig. 2). BAC clone C-2577N12 is located outside the apparent
deletion, in the proximity of D14S49 (Fig. 2). With BAC
C-2577N12, both copies of chromosome 14 were detected on a
chromosomal spread from Epstein–Barr Virus (EBV)-trans-
formed lymphocytes from patient III-1 of family IT1. BAC
R-552K16, in contrast, showed only one signal for chromo-
some 14; no signal was detected on any of the other
chromosomes, confirming that indeed there is a genomic
deletion segregating in this family. Since individuals I-1 and I-2
showed heterozygosity for several markers within the deletion
and had no family history of chorea, the most likely
explanation is that a de novo mutation in an oocyte of
individual I-2 was transmitted to individual II-3 and subse-
quently to individual III-1. The deletion was not seen in two
other unaffected subjects in this family who inherited the
maternal chromosome without the deletion. No deletions were
detected in families NL1 and US1 using the same STR markers
as above within the 1.2 Mb region.
A transcript map was constructed using sequence information
from available genome databases, and we searched for
expressed sequences within the 1.2 Mb deleted region. Five
transcripts were identified, encoding the following genes:
thyroid transcription factor 1 (TITF-1), MAPK upstream kinase
(MUK)-binding inhibitory protein (MBIP), NK-2 Drosophila
homologue 8 (NKX2.8), paired box gene 9 (PAX9) and solute
carrier family 25 member 21 (SLC25A21) (Fig. 2).
TITF-1 encompasses three exons spanning a genomic region
of 3.8 kb (25). Two major transcripts are produced, of 2.3 and
2.5 kb, encoding proteins of 371 and 401 amino acids,
respectively (26). The two protein isoforms differ only at their
N termini. The functional significance of these two protein
isoforms is unknown. After determining the intron–exon
boundaries of the TITF-1 gene, using available sequence
databases, the coding region including intron–exon boundaries
was sequenced on genomic DNA in patients from BHC
families NL1, US1 and UK1.
In family NL1, we detected a heterozygous C-to-A transver-
sion at position 727 (C727A) from the coding region (Fig. 4)
(reference sequence XM_048680), resulting in an amino acid
substitution of arginine by serine at codon 243 (R243S). The
mutation segregated with the disease in all available diagnosed
family members of family NL1 (Fig. 5). The mutation was not
seen in 200 control chromosomes from the general population.
From three subjects with an uncertain diagnosis (13),
individuals II-14 and III-13 inherited the mutation whereas
the mutation was absent in individual IV-4, demonstrating the
problems with clinical diagnosis of BHC; individual II-14 was
diagnosed in childhood with Sydenham’s chorea but this
diagnosis had been revised, in our original study, to BHC.
Subject III-13 did not show abnormalities at physical
examination at age 29 years, and has an unclear history of
choreic movements. Individual IV-4 had ataxic diplegia and no
obvious signs of chorea, but was only 3 years old at time of the
clinical investigation.
Family US1 showed a heterozygous G-to-T base change at
position 713 (G713T) (Fig. 4), resulting in a substitution of
tryptophan by leucine at codon 238 (W238L). The mutation
was seen in all available affected pedigree members but not in
unaffected family members (Fig. 5) or in 200 control
chromosomes from the general population.
Finally, a patient from family UK1 showed a heterozygous
deletion of a G at position 908 (DG908) (Fig. 4), resulting in a
frameshift of the reading frame (G303fsX77). This frameshift
Figure 4. Sequence electropherograms of mutations found in TITF-1. Both nor-
mal (left) and mutated (right) DNA and amino acid sequences are shown. From
top to bottom: the heterozygous C-to-A transversion at position 727 (C727A)
resulting in an amino acid substitution of arginine by serine at codon 243
(R243S) in family NL1; the heterozygous G-to-T base change at position
713 (G713T) resulting in a substitution of tryptophan by leucine at codon
238 (W238L) in family US1; the heterozygous deletion of a G at position
908 (DG908), resulting in a frameshift of the reading frame in family UK1
(G303fsX77).
974 Human Molecular Genetics, 2002, Vol. 11. No. 8
results in an aberrant protein starting at codon 303 extending
77 amino acids followed by a premature stop at codon 380
(22 amino acids missing). This mutation could not be detected
in two unaffected individuals of the family (Fig. 5) or in 200
control chromosomes from the general population. The
mutations were not seen in publicly available single nucleotide
polymorphism (SNP) and sequence databases or the Celera
human genome SNP database.
DISCUSSION
BHC is an autosomal dominant neurological disorder. At least
two loci exist, one on chromosome 14q and one unknown locus
(G.J. Breedveld et al., in preparation). We have identified
mutations in the TITF-1 gene on chromosome 14. The R243S
and W238L mutations in families NL1 and US1 are affecting
highly conserved amino acids in the homeodomain of the
TITF-1 gene (Fig. 6) (18). Homeodomains are DNA-binding
domains with a helix–turn–helix motif. The mutations are
located in helix 3, which upon binding to genomic DNA is
positioned within the wide groove of DNA and is responsible
for the majority of contacts between the target DNA sequence
and the TITF-1 protein (18,27,28).
The R243S mutation results in the change of a basic to a
neutral residue in this region and is directly adjacent to the
tyrosine residue (Y244) that is unique for the NKX class of
homeodomain proteins and determines the specificity of
binding to the DNA consensus sequence 50 T(C/T)AAGTG
30 (18,28). The W238L mutation is located at a hydrophobic
position of the third helix, which is important for the proper
positioning of the three helix subunits relative to each other
(28). Both mutations are close to the glutamine (Q240) and
asparagine (N241) residues, which are critical for base pair
contacts, and are therefore expected to affect the DNA-binding
properties of TITF-1 (18,27,28).
In contrast to the other mutations, DG908 is located within
the NK2-specific domain (NK2-SD). The function of this
domain is not known (18). The region is highly conserved in
NK2 genes and is proline-rich. It contains a hydrophobic core
with four valine residues in every second position and a
flanking basic protein : protein interface. In vitro, this domain is
not required for high-affinity sequence-specific DNA binding
(15,28), but it has been suggested that the region might dock
with factors that modulate transcriptional activation by TITF-1
in vivo (18). The frameshift introduced by this single base
deletion also causes an aberrant C-terminus of the protein. The
function of the C terminus of TITF-1 is unknown.
The genomic deletion in IT1 results in the complete loss of
one TITF-1 allele, suggesting that the chorea phenotype in this
family is caused by haploinsufficiency of the TITF-1 protein.
The mutations within conserved amino acids of the homeobox
DNA-binding domain of the transcription factor BHC most
likely result in a loss of DNA binding of TITF-1 and thus in the
loss of function of one TITF-1 allele.
In HD, signaling from the putamen to the external segment of
the globus pallidus through the so-called indirect pathway is
impaired owing to the loss of a subset of medium spiny neurons
as a result of an expanded polyglutamine stretch in the
huntingtin protein (29,30). The external segment of the globus
Figure 5. Segregation analysis of TITF-1 mutations found in families NL1 (C727A), US1 (G713T) and UK1 (G303fsX77). Black symbols represent BHC-affected
individuals, open symbols represent unaffected individuals and a question mark within a symbol denotes diagnosis unknown (II-9) or uncertain (II-14, III-13, IV-4).
For each mutation, both the normal and mutated nucleotides are indicated. The deleted nucleotide in UK 1 is indicated by a dash.
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pallidus is essential for limiting stimulation of neurons to the
thalamus. This alteration of basal ganglia activity results in a
greater degree of inhibition of thalamic outflow to the cortex.
Accepted models of basal ganglia function predict that loss of
this inhibition leads to hyperkinesia and choreic movements.
Hyperkinesia can also be expected when the ventral striatum
(pallidum) or neurons within the indirect pathway are not
properly connected, as in TITF-1 knockout mice (19,21). Mice
lacking TITF-1 expression die at birth and have severe lung,
thyroid and pituitary defects (19,21). In addition, TITF-1 is
essential for the development of the basal ganglia. In TITF-1-
deficient mice, the anlage from the ventral region of the
striatum is transformed into more dorsal structures and the
pallidum is not formed. TITF-1 is also required for the
production of basal forebrain TrkA-positive neurons and the
migration of GABAergic neurons to the cerebral cortex
(21,22).
BHC is, however, an autosomal dominant disease with a
loss of function of only one allele encoding the TITF-1
protein; the other allele is still fully functional. Furthermore,
hemizygous TITF-1 mice develop normally, although neuro-
logical abnormalities have not been studied in detail (19,21).
In patients, no abnormalities were detected on the available
cranial MRI studies. When these patients reach adulthood,
neurological symptoms usually become less severe or even
disappear. It is therefore likely that the disturbance in
development of patients is not as severe as in mice completely
lacking TITF-1 expression. Instead, the reduction of func-
tional TITF-1 protein could result in a delayed development
of the basal ganglia, delayed or reduced formation of basal
forebrain TrkA-positive neurons, and/or migration of GA-
BAergic neurons to the cerebral cortex, leading to a reduced
inhibition of the thalamus. The observation that clinical
involvement tends to decrease after reaching adolescence or
early adulthood suggests either that the brain compensates for
the defect by re-routing neuronal signaling or that the role of
TITF-1 with respect to the level of thyroid activity is
important during neuronal growth and development, but is
less critical during adult life. Resolution of this aspect
remains to be determined by future study.
Heterozygous deletions of chromosome 14q including
TITF-1 in humans are sometimes associated with thyroid
dysfunction, lung distress, midline defects, brain abnormalities
and movement disorders (31–35), but heterozygous TITF-1
mice do not show these abnormalities (21). In none of the
families described here were lung and/or thyroid problems
common, but thyroid function has not been systematically
investigated. In family US1, at least one member was
diagnosed with congenital hypothyroidism. In the families
described here, only the TITF-1 gene is affected or, as in family
IT1, five transcripts are deleted. A possible explanation would
be that in all previously described cases of TITF-1 deletions,
the deletions are much larger than found in our IT1 family and
that there is a correlation between the phenotype severity and
the size of the deletion intervals because other genes are deleted
that also contribute to the phenotype. Alternatively, environ-
mental factors or genetic background could influence the
phenotype. Given the nature and diversity of the identified
mutations affecting TITF-1, it will be of interest to extend the
available clinical data of patients to include thyroid dysfunc-
tion, lung distress, midline defects and structural brain
abnormalities in order to generate a genotype–phenotype
correlation.
Several families with incomplete penetrance for BHC have
been reported (8,36,37). The finding of a de novo deletion in
one of our families might offer an alternative explanation. The
reported segregation pattern might in fact be explained by
de novo deletions instead of incomplete penetrance.
The observation of four different mutations provides strong
evidence that mutations in TITF-1 are directly responsible for
BHC in the families reported here. Several families with early-
onset chorea are not linked to chromosome 14. Genes that
Figure 6. Alignment of the homeodomain and NK2-SD domain of the human TITF-1 protein with orthologs of other species (amino acids 180–338 form human
TITF-1). Completely or partly conserved amino acids are represented on a black or gray background respectively; arrows indicate the positions of the mutations
found in BHC family US1 (W238L), family NL1 (R243S) and family UK1 (G303fsX77). GenBank accession numbers: TTF1 dog: P43698; TTF1 rat: P23441;
TTF1 mouse: NM_009385.1; NKX2.1 chicken: AJ223618.1; NKX2.1 frog: AF250347.1; NKX2.1 zebrafish: AF321112.1.
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function within the TITF-1 pathway are now candidate genes
for the disorder in these families, and the specificity of target
DNA sequence of TITF-1 might help us to identify those genes.
In movement disorders such as Parkinson disease, tremors,
dystonias and HD, the basal ganglia play an important role. The
identification of mutations in TITF-1 resulting in BHC now
prompts studies targeted towards a better understanding of the
function of TITF-1 in the formation and function of the basal
ganglia. The current findings also allow us to differentiate BHC
from other movement disorders such as HD, ataxia telangiectasia
and benign essential myoclonus.
MATERIALS AND METHODS
Clinical studies
Clinical symptoms of families have been described elsewhere
(5,13,23,24). Medical ethical committees in all participating
research institutes approved this study.
FISH studies
FISH studies were performed on metaphases and interphases
derived from EBV-transformed peripheral blood lymphocytes
of BHC patient III-1 of family IT1. A two-color FISH with a
combination of a biotin-labeled probe (red) BAC C-2577N12
and a digoxigenin-labeled probe (green) BAC R-552K16 was
done using standard protocols with minor modifications.
Chromosomes were counterstained with 4,6-diamidino-2-
phenylindole (DAPI) (blue). Slides were examined under a
Leica Aristoplan fluorescence microscope and images were
captured using a Genetiscan Power Gene System (PSI Ltd,
Chester, UK).
STR marker development
Sequence data from BAC clones were downloaded from
GenBank (http://www.ncbi.nlm.nih.gov/Genbank/index.html).
STR sequences were selected by repeat length and type using
the program FileProcessor (J.W. van Dongen, 2001) available at
http://www.eur.nl/fgg/kgen. For databases and sequence analy-
sis, see http://www.eur.nl/fgg/kgen (choose ‘www links:
Databases and Sequence Analysis’).
Flanking primers were designed using Primer3 (http://www-
genome.wi.mit.edu/genome_software/other/primer3.html).
Heterozygosity of markers was determined using a panel of
200 independent chromosomes from the general population.
CGR46 and CGR67 were developed using the BAC R-116N8
sequence as source. CGR58 and CGR69 were developed from
BAC R-537P22. D14S1017N was developed from R-896J10.
The following primer sequences were used to amplify these
STRs:
D14S1017N; forward; tgttcttaccaaacaagcaaaca; reverse; ggaca-
aatgcatacacctgtga; size 146 bp.
CGR46; forward; ctgagcaagacaccgtcaga; reverse; cccaacaaa-
ctcccattatcc; size 199 bp.
CGR58; forward; tttttgccaattggttggat; reverse; gcctgggtgaca-
gaggtaca; size 194 bp.
CGR67; forward; ttggtttaattttcagctgggta; reverse; ggaaagaaa-
gagcactcaatgg; size 177 bp.
CGR69; forward; ttggcctttacaaacaaaagg; reverse; cttggtcaagg-
gccagatag; size 185 bp.
DNA isolation, PCR and genetic analysis
Genomic DNA was isolated from peripheral blood as described
previously (38). STR polymorphisms were amplified using
25 ng genomic DNA in 10 ml PCR reactions containing
1GeneAmp PCR Gold Buffer; 1.5 mM MgCl2; 25 ng of
fluorescent forward primer; 25 ng of unlabeled reverse primer
and 0.4 units of AmpliTaq Gold DNA polymerase (Applied
Biosystems). Initial denaturation was 10 min at 94C followed
by 32 cycles of 30 s denaturation at 94C, annealing at 55C
and 90s extension at 72C. PCR products were loaded on an
ABI3100 automated sequencer (filterset D), data were analyzed
using ABI GeneMapper 1.0 software. For haplotype analysis in
family IT1, phase was assigned on the basis of the minimum
number of recombination events.
Mutation analysis
Thyroid transcription factor 1 (TITF-1) has also been described
as thyroid-specific enhancer-binding protein (T/EBP) and
Nkx2.1. The genomic structure of TITF-1 was determined by
aligning cDNA (XM_048680) and genomic sequences from
BAC R-896J10. DNA was amplified using primers designed to
flanking intronic sequence (at least 50 base intronic sequence)
on both sides of an exon. The following primers were used:
Exon 1; forward; ggcagaagagaggcagacag; reverse; gggggag-
taacagaggagga;size: 363 bp.
Exon 2; forward; agcgaggcttcgccttcc; reverse; ctctcgccgcacctc-
ctg; size: 502 bp.
Exon 3_A; forward; gctaggctgcctgggtca; reverse; cgctgtcctgc-
tgcagtt; size: 462 bp.
Exon 3_B; forward; gttccagaaccaccgctaca; reverse; gtttgccgtc-
tttcaccag; size: 182 bp.
Exon 3_C; forward; caacaggctcagcagcagt; reverse; ggtggatggt-
ggtctgtgt; size: 453 bp.
PCR reactions for exons 1, 2, 3_A and 3_C were performed
in 50 ml containing 1GibcoBRL PCR buffer, 1.5 mM MgCl2,
0.01% W-1, 250 mm dNTP, 0.4 mm forward primer, 0.4 mM
reverse primer, 7% DMSO, 2.5 units Taq DNA polymerase
(GibcoBRL) and 50 ng genomic DNA. Cycle conditions: 5 min
at 94C; 10 cycles of 30 s denaturation at 94C, 30 s annealing
at 65C to 1C per cycle (70C to 1C per cycle for exon 2) and
40s extension at 72C; followed by 25 cycles of 30 s
denaturation at 94C, 30 s at 55C (60C for exon 2) and
40 s at 72C; final extension 5 min at 72C. Exon 3_B was
amplified in 20 ml containing 1GCII buffer (TaKaRa) 400 mM
dNTP, 1 mM forward primer, 1 mM reverse primer, 1 unit Taq
DNA polymerase (TaKaRa LA) and 50 ng genomic DNA.
Amplification was done using 1 min initial denaturation at
94C; 35 cycles 30 s at 94C, annealing 30 s at 55C, 2 min
extension at 72C, final extension 5 min at 72C. PCR products
were purified using the Millipore Multiscreen PCR plates, and
their approximate concentration was determined using Low
DNA Mass Ladder (GibcoBRL). After direct sequencing of
both strands using BigDye Terminator chemistry Version 4
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(Applied Biosystems), Sephadex G50 (Amersham Biosciences)
was used to purify the sequenced PCR products. Products were
loaded on an ABI3100 automated sequencer and analysis was
done with Sequence Navigator 1.0 for heterozygous base calls
and sequence alignment.
Testing of the base changes/deletion in exon 3 in family US1
and UK1 in remaining family members (if available) and 200
control chromosomes from the general population was done
using allele specific oligo hybridization (ASO). PCR products
containing exon_3A for family US1 and exon_3C for family
UK1 were blotted onto Hybond-N þ (Amersham Bio-
sciences). The blots were hybridized for 1 hour at 37C in
5 SSPE, 1% SDS and 0.05 mg/ml single-strand salmon
sperm DNA with either the normal or mutated sequence primer.
Filters were washed until a final stringency of 0.1 SSC/0.1%
SDS at 42C.
The following primers were used for ASO hybridization:
(G713T); W238L (US1); normal; agatctggttccag; mutated;
aagatcttgttccag
(DG908) (UK1); normal; ggcgggtgccc; deleted; ggcggtgcccc
The mutation (C727A) R243S was confirmed in family NL1
and 200 control chromosomes by digestion of 10 ml PCR
product in a 20 ml digestion reaction containing 1React1 and
10 units AluI (GibcoBRL). After digestion for 1 hour at 37C,
the products were run on a 2% agarose gel using 1 kb DNA
Ladder (GibcoBRL) as a size standard. Normal individuals
showed two fragments of 277 and 175 bp, respectively.
Affected individuals in family NL1 showed three fragments
of 277, 113 and 62 bases, respectively.
Amino acid alignment
Sequences were found by homology searches of the human
TITF-1 protein to the non-redundant database using the
BLAST algorithm. Aligning of the sequences was done using
the program Vector NTI, which implemented the Clustal_W
algorithm.
GenBank accession numbers
TITF-1 transcripts: HSU33749 for the short transcript and
XM_048680 for the longer transcript. R-537P22: AL079304;
R-552K16: AL121775; R-81F13: AL162464; R-964E11:
AL079303; R-896J10: AL132857; R-356A6: AL137226; R-
259K15: AL162511; R-116N18: AL133304; C-2577N12:
AL133316.
CGR58: dbSTS_Id 104379, GenBank_Accn G73508;
CGR69: dbSTS_Id 104378, GenBank_Accn G73507;
CGR46: dbSTS_Id 104381, GenBank_Accn G73510;
CGR67: dbSTS_Id 104380, GenBank_Accn G73509.
ACKNOWLEDGEMENTS
The authors wish to thank Drs M.F. Niermeijer and J.M.
Hoogeboom for clinical support, Ms Lakshmi Srinidhi, Patrizia
Rizzu and Bert Eussen for technical support, and Tom de
Vries-Lentsch for artwork. This work was supported by the
following grants: JanIvo Foundation to P.H. and NIH Grant
NS16367 to M.E.M.
REFERENCES
1. Haerer, A.F., Currier, R.D. and Jackson, J.F. (1967) Hereditary nonpro-
gressive chorea of early onset. N. Engl. J. Med., 276, 1220–1224.
2. Pincus, J.H. and Chutorian, A. (1967) Familial benign chorea with intention
tremor: a clinical entity. J. Pediatr., 70, 724–729.
3. Hayden, M.R. Huntington’s Chorea. Springer-Verlag, Berlin, 1981.
4. Harper, P.S. Huntington’s Disease. W.B. Saunders London, 1991.
5. Harper, P.S. (1978) Benign hereditary chorea. Clinical and genetic aspects.
Clin. Genet., 13, 85–95.
6. Haerer, A.F., Currier, R.D. and Jackson, J.F. (1966) Hereditary non-
progressive chorea of early onset. Neurology, 16, 307.
7. Bruyn, G.W. and Myrianthopoulos, N.C. (1986) Chronic juvenile
hereditary chorea (benign hereditary chorea of early onset). In Bruyn, G.W.,
Vinken, P.J. and Klawans, H.L. (eds), Extrapyramidial Disorders. Elsevier
Science, Amsterdam, Vol. 5, pp. 335–348.
8. Chun, R.W., Daly, R.F., Mansheim, B.J., Jr., Wolcott, G.J. (1973) Benign
familial chorea with onset in childhood. JAMA, 225, 1603–1607.
9. MacMillan, J.C., Morrison, P.J., Nevin, N.C., Shaw, D.J., Harper, P.S.,
Quarrell, O.W. and Snell, R.G. (1993) Identification of an expanded CAG
repeat in the Huntington’s disease gene (IT15) in a family reported to have
benign hereditary chorea. J. Med. Genet., 30, 1012–1013.
10. Klein, C., Wenning, G.K., Quinn, N.P. and Marsden, C.D. (1996) Ataxia
without telangiectasia masquerading as benign hereditary chorea. Mov.
Disord., 11, 217–220.
11. Zambrino, C.A., La Bounora, I., Lanzi, G. and Burgio, F.R. (1984) Corea
benigna familiare: a proposito di due casi. G. Neuropsichiatr Eta Evol., 4,
81–87.
12. Schrag, A., Quinn, N.P., Bhatia, K.P. and Marsden, C.D. (2000) Benign
hereditary chorea – entity or syndrome? Mov. Disord., 15, 280–288.
13. de Vries, B.B., Arts, W.F., Breedveld, G.J., Hoogeboom, J.J., Niermeijer
M.F. and Heutink, P. (2000) Benign hereditary chorea of early onset maps
to chromosome 14q. Am. J. Hum. Genet., 66, 136–142.
14. Fernandez, M., Raskind, W., Matsushita, M., Wolff, J., Lipe, H. and Bird, T.
(2001) Hereditary benign chorea: clinical and genetic features of a distinct
disease. Neurology, 57, 106–110.
15. Guazzi, S., Price, M., De Felice, M., Damante, G., Mattei, M.G. and Di
Lauro, R. (1990) Thyroid nuclear factor 1 (TTF-1) contains a home-
odomain and displays a novel DNA binding specificity. EMBO J., 9, 3631–
3639.
16. Mizuno, K., Gonzalez, F.J. and Kimura, S. (1991) Thyroid-specific
enhancer-binding protein (T/EBP): cDNA cloning, functional character-
ization, and structural identity with thyroid transcription factor TTF-1. Mol.
Cell. Biol., 11, 4927–4933.
17. Ikeda, K., Clark, J.C., Shaw-White, J.R., Stahlman, M.T., Boutell, C.J. and
Whitsett, J.A. (1995) Gene structure and expression of human thyroid
transcription factor-1 in respiratory epithelial cells. J. Biol. Chem., 270,
8108–8114.
18. Harvey, R.P. (1996) NK-2 homeobox genes and heart development. Dev.
Biol., 178, 203–216.
19. Kimura, S., Hara, Y., Pineau, T., Fernandez-Salguero, P., Fox, C.H., Ward,
J.M. and Gonzalez, F.J. (1996) The T/ebp null mouse: thyroid-specific
enhancer-binding protein is essential for the organogenesis of the thyroid,
lung, ventral forebrain, and pituitary. Genes Dev., 10, 60–69.
20. Takuma, N., Sheng, H.Z., Furuta, Y., Ward, J.M., Sharma, K., Hogan, B.L.,
Pfaff, S.L., Westphal, H., Kimura, S. and Mahon, K.A. (1998) Formation of
Rathke’s pouch requires dual induction from the diencephalon. Develop-
ment, 125, 4835–4840.
21. Sussel, L., Marin, O., Kimura, S. and Rubenstein, J.L. (1999) Loss
of Nkx2.1 homeobox gene function results in a ventral to dorsal
molecular respecification within the basal telencephalon: evidence for a
transformation of the pallidum into the striatum. Development, 126,
3359–3370.
22. Pleasure, S.J., Anderson, S., Hevner, R., Bagri, A., Marin, O., Lowenstein,
D.H. and Rubenstein, J.L. (2000) Cell migration from the ganglionic
eminences is required for the development of hippocampal GABAergic
interneurons. Neuron, 28, 727–740.
23. Mussell, G.M., Dure, L.S. and Percy, A.K. (1995) Benign familial chorea:
clinical characterization of an Alabama pedigree. Neurology, 45, A184.
24. Guala, A., Nocita, G., Di Maria, E., Mandich, P., Provera, S., Cerruti
Mainardi, P. and Pastore, G. (2001) Benign hereditary chorea: a rare cause
of disability. Riv. Ital. Pediatr., 27(Suppl.), 150–152.
978 Human Molecular Genetics, 2002, Vol. 11. No. 8
25. Hamdan, H., Liu, H., Li, C., Jones, C., Lee, M., deLemos, R., Minoo, P.
(1998) Structure of the human Nkx2.1 gene. Biochim. Biophys. Acta, 1396,
336–348.
26. Li, C., Cai, J., Pan, Q., Minoo, P. (2000) Two functionally distinct forms of
NKX2.1 protein are expressed in the pulmonary epithelium. Biochem.
Biophys. Res. Commun., 270, 462–468.
27. Gruschus, J.M., Tsao, D.H., Wang, L.H., Nirenberg, M. and Ferretti, J.A.
(1997) Interactions of the vnd/NK-2 homeodomain with DNA by nuclear
magnetic resonance spectroscopy: basis of binding specificity. Biochem-
istry, 36, 5372–5380.
28. Damante, G., Fabbro, D., Pellizzari, L., Civitareale, D., Guazzi, S.,
Polycarpou-Schwartz, M., Cauci, S., Quadrifoglio, F., Formisano, S. and Di
Lauro, R. (1994) Sequence-specific DNA recognition by the thyroid
transcription factor-1 homeodomain. Nucleic Acids Res., 22, 3075–3083.
29. Albin, R.L., Young, A.B. and Penney, J.B. (1989) The functional anatomy
of basal ganglia disorders. Trends Neurosci., 12, 366–375.
30. The Huntington’s Disease Collaborative Research Group (1993) A novel
gene containing a trinucleotide repeat that is expanded and unstable on
Huntington’s disease chromosomes. Cell, 72, 971–983.
31. Iwatani, N., Mabe, H., Devriendt, K., Kodama, M. and Miike, T. (2000)
Deletion of NKX2.1 gene encoding thyroid transcription factor-1 in
two siblings with hypothyroidism and respiratory failure. J. Pediatr., 137,
272–276.
32. Devriendt, K., Vanhole, C., Matthijs, G. and de Zegher, F. (1998)
Deletion of thyroid transcription factor-1 gene in an infant with
neonatal thyroid dysfunction and respiratory failure. N. Engl. J. Med.,
338, 1317–1318.
33. Devriendt, K., Fryns, J.P. and Chen, C.P. (1998) Holoprosencephaly in
deletions of proximal chromosome 14q. J. Med. Genet., 35, 612.
34. Kamnasaran, D., O’Brien, P.C., Schuffenhauer, S., Quarrell, O., Lupski,
J.R., Grammatico, P., Ferguson-Smith, M.A. and Cox, D.W. (2001)
Defining the breakpoints of proximal chromosome 14q rearrangements in
nine patients using flow-sorted chromosomes. Am. J. Med. Genet., 102,
173–182.
35. Sutton, V.R. and Shaffer, L.G. (2000) Search for imprinted regions
on chromosome 14: comparison of maternal and paternal UPD cases
with cases of chromosome 14 deletion. Am. J. Med. Genet., 93, 381–387.
36. Nutting, P.A., Cole, B.R. and Schimke, R.N. (1969) Benign, recessively
inherited choreo athetosis of early onset. J. Med. Genet., 6, 408–410.
37. Damasio, H., Antunes, L. and Damasio, A.R. (1977) Familial non-
progressive involuntary movements of childhood. Ann. Neurol., 1,
602–603.
38. Miller, S.A., Dykes, D.D. and Polesky, H.F. (1988) A simple salting out
procedure for extracting DNA from human nucleated cells. Nucleic Acids
Res., 16, 1215.
Human Molecular Genetics, 2002, Vol. 11. No. 8 979

